Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study

被引:0
|
作者
Tammemagi, Martin C. [1 ]
Schmidt, Heidi [2 ]
Martel, Simon [3 ]
McWilliams, Annette [4 ,5 ]
Goffin, John R. [6 ]
Johnston, Michael R. [7 ]
Nicholas, Garth [8 ]
Tremblay, Alain [9 ]
Bhatia, Rick [10 ]
Liu, Geoffrey [2 ]
Soghrati, Kam [2 ]
Yasufuku, Kazuhiro [2 ]
Hwang, David M. [2 ]
Laberge, Francis [3 ]
Gingras, Michel [3 ]
Pasian, Sergio [3 ]
Couture, Christian [3 ]
Mayo, John R. [11 ]
Fauerbach, Paola V. Nasute [12 ]
Atkar-Khattra, Sukhinder [13 ]
Peacock, Stuart J. [13 ]
Cressman, Sonya [13 ]
Ionescu, Diana [13 ]
English, John C. [11 ]
Finley, Richard J. [11 ]
Yee, John [11 ]
Puksa, Serge [6 ]
Stewart, Lori [6 ]
Tsai, Scott [6 ]
Haider, Ehsan [14 ]
Boylan, Colm [14 ]
Cutz, Jean-Claude [6 ]
Manos, Daria [7 ]
Xu, Zhaolin [7 ]
Goss, Glenwood D. [8 ]
Seely, Jean M. [8 ]
Amjadi, Kayvan [8 ]
Sekhon, Harmanjatinder S. [8 ]
Burrowes, Paul [9 ]
MacEachern, Paul [9 ]
Urbanski, Stefan [9 ]
Sin, Don D. [15 ]
Tan, Wan C. [15 ]
Leighl, Natasha B. [2 ]
Shepherd, Frances A. [2 ]
Evans, William K. [6 ]
Tsao, Ming-Sound [2 ]
Lam, Stephen [11 ,13 ]
机构
[1] Brock Univ, Dept Hlth Sci, St Catharines, ON, Canada
[2] Univ Hlth Network, Toronto, ON, Canada
[3] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada
[4] Fionna Stanley Hosp, Perth, WA, Australia
[5] Sir Charles Gairdner Hosp, Perth, WA, Australia
[6] Juravinski Canc Ctr, Hamilton, ON, Canada
[7] Dalhousie Univ, Halifax, NS, Canada
[8] Ottawa Hosp, Canc Ctr, Ottawa, ON, Canada
[9] Univ Calgary, Calgary, AB, Canada
[10] Mem Univ, St John, NF, Canada
[11] Vancouver Gen Hosp, Vancouver, BC, Canada
[12] Queens Univ, Kingston, ON, Canada
[13] British Columbia Canc Agcy, Vancouver, BC V5Z 1L3, Canada
[14] St Josephs Healthcare, Hamilton, ON, Canada
[15] St Pauls Hosp, Vancouver, BC, Canada
关键词
ELIGIBILITY CRITERIA; COST-EFFECTIVENESS; TRIAL; CT; PREDICTION; INDIVIDUALS; INTERVAL; PREVALENCE; VALIDATION; MORTALITY;
D O I
10.1016/S1470-2045(17)30597-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Results from retrospective studies indicate that selecting individuals for low-dose CT lung cancer screening on the basis of a highly predictive risk model is superior to using criteria similar to those used in the National Lung Screening Trial (NLST; age, pack-year, and smoking quit-time). We designed the Pan-Canadian Early Detection of Lung Cancer (PanCan) study to assess the efficacy of a risk prediction model to select candidates for lung cancer screening, with the aim of determining whether this approach could better detect patients with early, potentially curable, lung cancer. Methods We did this single-arm, prospective study in eight centres across Canada. We recruited participants aged 50-75 years, who had smoked at some point in their life (ever-smokers), and who did not have a self-reported history of lung cancer. Participants had at least a 2% 6-year risk of lung cancer as estimated by the PanCan model, a precursor to the validated PLCOm2012 model. Risk variables in the model were age, smoking duration, pack-years, family history of lung cancer, education level, body-mass index, chest x-ray in the past 3 years, and history of chronic obstructive pulmonary disease. Individuals were screened with low-dose CT at baseline (T0), and at 1 (T1) and 4 (T4) years post-baseline. The primary outcome of the study was incidence of lung cancer. This study is registered with ClinicalTrials. gov, number NCT00751660. Findings 7059 queries came into the study coordinating centre and were screened for PanCan risk. 15 were duplicates, so 7044 participants were considered for enrolment. Between Sept 24, 2008, and Dec 17, 2010, we recruited and enrolled 2537 eligible ever-smokers. After a median follow-up of 5.5 years (IQR 3.2-6.1), 172 lung cancers were diagnosed in 164 individuals (cumulative incidence 0.065 [95% CI 0.055-0.075], incidence rate 138.1 per 10 000 person-years [117.8-160.9]). There were ten interval lung cancers (6% of lung cancers and 6% of individuals with cancer): one diagnosed between T0 and T1, and nine between T1 and T4. Cumulative incidence was significantly higher than that observed in NLST (4.0%; p<0.0001). Compared with 593 (57%) of 1040 lung cancers observed in NLST, 133 (77%) of 172 lung cancers in the PanCan Study were early stage (I or II; p<0.0001). Interpretation The PanCan model was effective in identifying individuals who were subsequently diagnosed with early, potentially curable, lung cancer. The incidence of cancers detected and the proportion of early stage cancers in the screened population was higher than observed in previous studies. This approach should be considered for adoption in lung cancer screening programmes.
引用
收藏
页码:1523 / 1531
页数:9
相关论文
共 50 条
  • [21] Urinary Metabolite Risk Biomarkers of Lung Cancer: A Prospective Cohort Study
    Haznadar, Majda
    Cai, Qiuyin
    Krausz, Kristopher W.
    Bowman, Elise D.
    Margono, Ezra
    Noro, Rintaro
    Thompson, Matthew D.
    Mathe, Ewy A.
    Munro, Heather M.
    Steinwandel, Mark D.
    Gonzalez, Frank J.
    Blot, William J.
    Harris, Curtis C.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (06) : 978 - 986
  • [22] Prospective evaluation of watchful waiting for early-stage lung cancer with ground-glass opacity: a single-arm confirmatory multicenter study: Japan Clinical Oncology Group study JCOG1906 (EVERGREEN study)
    Miyoshi, Tomohiro
    Aokage, Keiju
    Wakabayashi, Masashi
    Shimoyama, Ryo
    Kataoka, Tomoko
    Fukuda, Haruhiko
    Watanabe, Shun-ichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (08) : 1330 - 1333
  • [23] Sleep disordered breathing and nocturnal hypoxemia are very prevalent in a lung cancer screening population and may condition lung cancer screening findings: results of the prospective Sleep Apnea In Lung Cancer Screening (SAILS) study
    Perez-Warnisher, M. T.
    Cabezas, E.
    Troncoso, M. F.
    Gomez, T.
    Melchor, R.
    Pinillos, E. J.
    El Hachem, A.
    Gotera, C.
    Rodriguez, P.
    Mahillo, I.
    Gonzalez-Mangado, N.
    Peces-Barba, G.
    Seijo, L. M.
    SLEEP MEDICINE, 2019, 54 : 181 - 186
  • [24] A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
    Tanaka, Hisashi
    Taima, Kageaki
    Morimoto, Takeshi
    Tanaka, Yoshihito
    Itoga, Masamichi
    Nakamura, Kunihiko
    Hayashi, Akihito
    Kumagai, Mika
    Yasugahira, Hideo
    Mikuniya, Megumi
    Okudera, Koichi
    Takanashi, Shingo
    Tasaka, Sadatomo
    BMC CANCER, 2017, 17
  • [25] Changes in shunt, ventilation/perfusion mismatch, and lung aeration with PEEP in patients with ARDS: a prospective single-arm interventional study
    Karbing, Dan Stieper
    Panigada, Mauro
    Bottino, Nicola
    Spinelli, Elena
    Protti, Alessandro
    Rees, Stephen Edward
    Gattinoni, Luciano
    CRITICAL CARE, 2020, 24 (01)
  • [26] Home energy efficiency and radon related risk of lung cancer: modelling study
    Milner, James
    Shrubsole, Clive
    Das, Payel
    Jones, Benjamin
    Ridley, Ian
    Chalabi, Zaid
    Hamilton, Ian
    Armstrong, Ben
    Davies, Michael
    Wilkinson, Paul
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 348 : 1 - 12
  • [27] Changes in shunt, ventilation/perfusion mismatch, and lung aeration with PEEP in patients with ARDS: a prospective single-arm interventional study
    Dan Stieper Karbing
    Mauro Panigada
    Nicola Bottino
    Elena Spinelli
    Alessandro Protti
    Stephen Edward Rees
    Luciano Gattinoni
    Critical Care, 24
  • [28] Pilot study on use of home telephoning to identify and recruit high-risk individuals for lung cancer screening
    Veronesi, Giulia
    Colombo, Paolo
    Novellis, Pierluigi
    Crepaldi, Alessandro
    Lutman, Romano Fabio
    Dieci, Elisa
    Profili, Manuel
    Siracusano, Licia
    Alloisio, Marco
    LUNG CANCER, 2017, 105 : 39 - 41
  • [29] Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study
    Marquette, Charles-Hugo
    Boutros, Jacques
    Benzaquen, Jonathan
    Ferreira, Marion
    Pastre, Jean
    Pison, Christophe
    Padovani, Bernard
    Bettayeb, Faiza
    Fallet, Vincent
    Guibert, Nicolas
    Basille, Damien
    Ilie, Marius
    Hofman, Veronique
    Hofman, Paul
    LANCET RESPIRATORY MEDICINE, 2020, 8 (07) : 709 - 716
  • [30] Considerations regarding the selection, sampling, extraction, analysis, and modelling of biomarkers in exhaled breath for early lung cancer screening
    Lundberg, Robert
    Dahlen, Johan
    Lundeberg, Thomas
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2025, 260